Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167102 · ClinicalTrials.gov registry record · NA
Alefacept in Patients With Severe Scalp Alopecia Areata
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT00167102 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 45 participants.
The verdict
NCT00167102, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and therapeutic aspects, suggest that alefacept, which has been shown to be a safe and statistically significant beneficial therapeutic modality for the treatment of psoriasis, may have therapeutic value in alopecia areata.
Interventions
- DRUG Alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167102
The ClinicalTrials.gov registry entry for NCT00167102 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alefacept is the first listed.
NCT00167102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167102 about?
NCT00167102 is a clinical study titled "Alefacept in Patients With Severe Scalp Alopecia Areata". The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and therapeutic aspects, suggest that alefacept, which has be...
What is the current status of trial NCT00167102?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2005-07. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00167102?
The interventions under investigation include: Alefacept (DRUG).
Who is sponsoring clinical trial NCT00167102?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.